Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 152

1.

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S.

Lancet Oncol. 2016 Jun;17(6):727-37. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4.

PMID:
27155740
2.

Enhancing active surveillance of prostate cancer: the potential of exercise medicine.

Galvão DA, Taaffe DR, Spry N, Gardiner RA, Taylor R, Risbridger GP, Frydenberg M, Hill M, Chambers SK, Stricker P, Shannon T, Hayne D, Zopf E, Newton RU.

Nat Rev Urol. 2016 May;13(5):258-65. doi: 10.1038/nrurol.2016.46. Epub 2016 Mar 8. Review.

PMID:
26954333
3.

Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation.

Wall BA, Galvão DA, Fatehee N, Taaffe DR, Spry N, Joseph D, Newton RU.

Adv Urol. 2015;2015:976235. doi: 10.1155/2015/976235. Epub 2015 Oct 26.

4.

Acute Inflammatory Response to Low-, Moderate-, and High-Load Resistance Exercise in Women With Breast Cancer-Related Lymphedema.

Cormie P, Singh B, Hayes S, Peake JM, Galvão DA, Taaffe DR, Spry N, Nosaka K, Cornish B, Schmitz KH, Newton RU.

Integr Cancer Ther. 2015 Nov 17. pii: 1534735415617283. [Epub ahead of print]

PMID:
26582633
5.

Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data.

Delahunt B, Egevad L, Srigley JR, Steigler A, Murray JD, Atkinson C, Matthews J, Duchesne G, Spry NA, Christie D, Joseph D, Attia J, Denham JW.

Pathology. 2015 Oct;47(6):520-5. doi: 10.1097/PAT.0000000000000318.

PMID:
26325671
6.

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial.

Denham JW, Steigler A, Joseph D, Lamb DS, Spry NA, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai KH, Gogna NK, Gill S, Tan H, Kearvell R, Murray J, Ebert M, Haworth A, Kennedy A, Delahunt B, Oldmeadow C, Holliday EG, Attia J.

Radiother Oncol. 2015 Jun;115(3):301-7. doi: 10.1016/j.radonc.2015.05.016. Epub 2015 Jun 10.

PMID:
26072289
7.

Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases.

Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA.

Prostate Cancer Prostatic Dis. 2015 Jun;18(2):196. doi: 10.1038/pcan.2015.6. No abstract available.

PMID:
25964200
8.

The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancer.

Buffart LM, Newton RU, Chinapaw MJ, Taaffe DR, Spry NA, Denham JW, Joseph DJ, Lamb DS, Brug J, Galvão DA.

Cancer. 2015 Aug 15;121(16):2821-30. doi: 10.1002/cncr.29406. Epub 2015 Apr 17. Erratum in: Cancer. 2015 Sep 15;121(18):3367-8.

PMID:
25891302
9.

Resistance training and cancer survival.

Christensen JF, Spry NA, Galvão DA.

Mayo Clin Proc. 2014 Oct;89(10):1465. doi: 10.1016/j.mayocp.2014.08.001. No abstract available.

PMID:
25282433
10.

Protocol for the RT Prepare Trial: a multiple-baseline study of radiation therapists delivering education and support to women with breast cancer who are referred for radiotherapy.

Halkett G, O'Connor M, Aranda S, Jefford M, Spry N, Shaw T, Moorin R, Schofield P.

BMJ Open. 2014 Aug 18;4(8):e006116. doi: 10.1136/bmjopen-2014-006116.

11.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.

Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A.

Lancet Oncol. 2014 Sep;15(10):1076-89. doi: 10.1016/S1470-2045(14)70328-6. Epub 2014 Aug 14.

PMID:
25130995
12.

Technical quality assurance during the TROG 03.04 RADAR prostate radiotherapy trial: are the results reflected in observed toxicity rates?

Ebert MA, Bulsara M, Haworth A, Kearvell R, Richardson S, Kennedy A, Spry NA, Bydder SA, Joseph DJ, Denham JW.

J Med Imaging Radiat Oncol. 2015 Feb;59(1):99-108. doi: 10.1111/1754-9485.12212. Epub 2014 Aug 1.

PMID:
25082363
13.

The relationship between BPAQ-derived physical activity and bone density of middle-aged and older men.

Bolam KA, Beck BR, Adlard KN, Skinner TL, Cormie P, Galvão DA, Spry N, Newton RU, Taaffe DR.

Osteoporos Int. 2014 Nov;25(11):2663-8. doi: 10.1007/s00198-014-2797-z. Epub 2014 Jul 4.

PMID:
24993816
14.

A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.

Pearse M, Fraser-Browne C, Davis ID, Duchesne GM, Fisher R, Frydenberg M, Haworth A, Jose C, Joseph DJ, Lim TS, Matthews J, Millar J, Sidhom M, Spry NA, Tang CI, Turner S, Williams SG, Wiltshire K, Woo HH, Kneebone A.

BJU Int. 2014 Mar;113 Suppl 2:7-12. doi: 10.1111/bju.12623.

15.

Maximal exercise testing of men with prostate cancer being treated with androgen deprivation therapy.

Wall BA, Galvão DA, Fatehee N, Taaffe DR, Spry N, Joseph D, Newton RU.

Med Sci Sports Exerc. 2014 Dec;46(12):2210-5. doi: 10.1249/MSS.0000000000000353.

PMID:
24694745
16.

Improving sexual health in men with prostate cancer: randomised controlled trial of exercise and psychosexual therapies.

Cormie P, Chambers SK, Newton RU, Gardiner RA, Spry N, Taaffe DR, Joseph D, Hamid MA, Chong P, Hughes D, Hamilton K, Galvão DA.

BMC Cancer. 2014 Mar 18;14:199. doi: 10.1186/1471-2407-14-199.

17.

Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.

Denham JW, Nowitz M, Joseph D, Duchesne G, Spry NA, Lamb DS, Matthews J, Turner S, Atkinson C, Tai KH, Gogna NK, Kenny L, Diamond T, Smart R, Rowan D, Moscato P, Vimieiro R, Woodfield R, Lynch K, Delahunt B, Murray J, D'Este C, McElduff P, Steigler A, Kautto A, Ball J.

BJU Int. 2014 Sep;114(3):344-53. doi: 10.1111/bju.12497. Epub 2014 Feb 11.

18.

Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial.

Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, Chambers SK, Newton RU.

BJU Int. 2015 Feb;115(2):256-66. doi: 10.1111/bju.12646. Epub 2014 Jul 27.

19.

Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study.

Cormie P, Galvão DA, Spry N, Joseph D, Taaffe DR, Newton RU.

Support Care Cancer. 2014 Jun;22(6):1537-48. doi: 10.1007/s00520-013-2103-1. Epub 2014 Jan 15.

PMID:
24424484
20.

Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.

Moseshvili E, Joseph DJ, Spry NA, Cohen RJ, Abreu A, Kautto A, Denham JW.

J Med Imaging Radiat Oncol. 2014 Aug;58(4):497-502. doi: 10.1111/1754-9485.12134. Epub 2014 Jan 13.

PMID:
24418365
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk